dacepton solution for injection
ever pharma jena gmbh - apomorphine hydrochloride hemihydrate - solution for injection - 10mg/ml
prunetec
max stanton moore - tebuconazole - tebuconazole 10 g/litre - fungicide
liposomal doxorubicin sun doxorubicin hydrochloride 50mg/25ml liposome injection concentrate glass vial
sun pharma anz pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: hydrochloric acid; sodium hydroxide; sucrose; histidine; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; hydrogenated soy phosphatidylcholine; ammonium sulfate; ethanol; water for injections - liposomal doxorubicin sun, as monotherapy, is indicated for the treatment of metastatic breast cancer.,liposomal doxorubicin sun is also indicated for the treatment of:,? advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.,? aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.,liposomal doxorubicin sun may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline).,liposomal doxorubicin sun is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
liposomal doxorubicin sun doxorubicin hydrochloride 20mg/10ml liposome injection concentrate glass vial
sun pharma anz pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: water for injections; cholesterol; ethanol; hydrogenated soy phosphatidylcholine; ammonium sulfate; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; histidine; hydrochloric acid; sodium hydroxide; sucrose - liposomal doxorubicin sun, as monotherapy, is indicated for the treatment of metastatic breast cancer.,liposomal doxorubicin sun is also indicated for the treatment of:,? advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.,? aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.,liposomal doxorubicin sun may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). liposomal doxorubicin sun is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.
caelyx doxorubicin hydrochloride 50mg/25ml injection, concentrated
baxter healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: hydrogenated soy phosphatidylcholine; histidine; hydrochloric acid; ammonium sulfate; cholesterol; water for injections; sodium hydroxide; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; sucrose - indications: for the treatment of: (1) advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 29 february 2008: caelyx, as monotherapy, is indicated for the treatment of metastatic breast cancer. caelyx is also indicated for the treatment of: advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.
caelyx doxorubicin hydrochloride 20mg/10ml injection, concentrated
baxter healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: ammonium sulfate; histidine; water for injections; sodium hydroxide; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; sucrose; hydrogenated soy phosphatidylcholine; hydrochloric acid - for the treatment of aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm) and extensive mucocutaneous or visceral disease. caelyx may be used for first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 21 september 2001: for the treatment of: (1) advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 29 february 2008: caelyx, as monotherapy, is indicated for the treatment of metastatic breast cancer. caelyx is also indicated for the treatment of: advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.
3a-fer alu-alu 10 cap
3a pharma. - carbonyl iron,vit.b12,vit.c,folic acid,zinc sulph. - cap - 100mg,15mcg,150mg,1mg,61.8mg - 10
adcob-cz 200ml sus
kinedex hc. - carbonyl iron,vit.b12,folic acid,zinc sulph. - sus - 50mg,6mcg,0.5mg,11mg - 200ml
adenoxyl-hb 10 tab
pulse - carbonyl iron,vit.b12,folic acid,zinc sulph. - tab - 60mg,500mcg(adenosylcobalamin),1.5mg,20mg(as zinc oxide) - 10
adiron 2*15 cap
destin lab - carbonyl iron,vit.b12,vit.c,folic acid,zinc sulph. - cap - 100mg,5mcg,75mg,1.5mg,25mg - 2*15